US FDA hits Cephalon with complete response letter for jet lag drug
This article was originally published in Scrip
Executive Summary
The US FDA has hit Cephalon with a complete response letter over its sNDA for Nuvigil (armodafinil) for the treatment of patients with excessive sleepiness associated with jet lag resulting from eastbound travel, raising queries over the data included in the application.